Melanoma Trial, Recruiting NCT05478876 Sponsor: CNAO National Center of Oncological Hadrontherapy Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT05478876
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have had a tissue biopsy confirming their diagnosis
  • People whose cancer has not spread to the skin
  • People whose cancer has spread to nearby lymph nodes, but only if those lymph nodes are limited to the groin and pelvis area
  • People between the ages of 20 and 80
  • People who are reasonably active and able to carry out daily activities (as measured by a standard medical scale called ECOG, scoring 0–2) (confirm with trial site)
  • People who have no signs of cancer that has spread to distant parts of the body
  • People whose cancer is at least 5 mm away from the rectum and bladder wall
  • People who have not previously received radiation therapy
  • People who are willing and able to give written consent to participate
  • People who are able to understand what the trial involves and what it means for them
  • People who have had molecular and genetic testing done on their cancer (confirm with trial site)
  • People who have had standard tests done to determine the current stage of their disease

Who may not be able to join:

  • People who have a hip replacement, metal implants, or any other condition that would prevent clear medical imaging needed to plan treatment
  • People with psychological or other conditions that would prevent them from giving informed consent
  • People who have previously had another cancer, unless they have been free of that cancer for at least 3 years
  • People who are unable to have an MRI scan for any reason
  • People who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Amelia Barcellini, MD, CNAO National Center of Oncological Hadrontherapy

Phone: 0039 0382078501

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
CNAO National Center of Oncological Hadrontherapy
Registry
ClinicalTrials.gov
Start date
3 September 2020
Est. completion
1 September 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

progression free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov